Edition:
United Kingdom

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

4.99EUR
4:35pm BST
Change (% chg)

€-0.00 (-0.10%)
Prev Close
€5.00
Open
€5.08
Day's High
€5.08
Day's Low
€4.90
Volume
19,699
Avg. Vol
23,958
52-wk High
€9.13
52-wk Low
€4.52

Latest Key Developments (Source: Significant Developments)

Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros
Tuesday, 17 Sep 2019 

Sept 18 (Reuters) - ERYTECH PHARMA : :REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO.H1 TOTAL OPERATING LOSS EUR 30.2 MLN VS LOSS EUR 21.9 MLN YEAR AGO.DR. JEAN PAUL KRESS APPOINTED AS CHAIRMAN.TRYBECA1, PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER, PROGRESSING ON PLAN.CASH POSITION OF EUR 94.5 MILLION AT THE END OF JUNE.  Full Article

Erytech Pharma SA Files For Stock Shelf Of Upto $100 Mln
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Erytech Pharma SA ::ERYTECH PHARMA SA FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies
Tuesday, 25 Jun 2019 

June 25 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION.ERYTECH HAS GRANTED TO SQZ AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP ANTIGEN-SPECIFIC IMMUNE MODULATING THERAPIES EMPLOYING RBC-BASED APPROACHES.ERYTECH IS ELIGIBLE TO RECEIVE UP TO $57 MLN IN COMBINED UPFRONT AND POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FOR FIRST PRODUCT SUCCESSFULLY DEVELOPED BY SQZ UNDER THIS AGREEMENT.ERYTECH ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES, AND UP TO $50 MLN IN COMMERCIAL MILESTONE PAYMENTS RELATED TO EACH ADDITIONAL APPROVED PRODUCT OR APPROVED INDICATION.  Full Article

ERYTECH Partners With New York Blood Center For Red Blood Cell Supply And Research
Friday, 16 Nov 2018 

Nov 16 (Reuters) - ERYTECH PHARMA SA ::NEW YORK BLOOD CENTER (NYBC)TO BECOME LONG-TERM SUPPLIER OF DONOR RED BLOOD CELLS (RBC) TO ERYTECH.WILL ENABLE ERYTECH TO DIVERSIFY AND BROADEN ITS SUPPLY OF RBC SOURCE MATERIALS FOR PRODUCTION OF ERYASPASE .WILL ALSO ENABLE PRODUCTION OF FUTURE PRODUCT CANDIDATES DERIVED FROM ITS PROPRIETARY ERYCAPS PLATFORM.  Full Article

Erytech: Enrollment Of 1st Patients In Phase 3 Clinical Trial Of Eryaspase
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES ENROLLMENT OF FIRST PATIENTS IN PHASE 3 CLINICAL TRIAL EVALUATING ERYASPASE FOR THE TREATMENT OF SECOND LINE PANCREATIC CANCER.TRYBECA1 TRIAL WILL ENROLL APPROXIMATELY 500 PATIENTS.PATIENT ENROLLMENT HAS STARTED AS PLANNED.FIRST THREE ENROLLED PATIENTS MARK INITIATION OF TRIAL IN EUROPE.EARLY NEXT YEAR, WE EXPECT SITES IN UNITED STATES WILL BEGIN ENROLLING AS WELL.  Full Article

BVF Partners Reports 20.2 Pct Stake In Erytech Pharma SA As Of July 16
Thursday, 19 Jul 2018 

July 19 (Reuters) - BVF Partners LP::BVF PARTNERS LP REPORTS 20.2 PERCENT STAKE IN ERYTECH PHARMA SA AS OF JULY 16 - SEC FILING.BVF PARTNERS LP PURCHASED ERYTECH PHARMA SA SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Oncodesign Concludes A Partnership With Erytech In Oncology
Tuesday, 27 Mar 2018 

March 27 (Reuters) - ONCODESIGN SA ::ONCODESIGN CONCLUDES A LONG TERM SERVICE-BASED PARTNERSHIP WITH ERYTECH IN ONCOLOGY.PARTNERSHIP AIMS TO ESTABLISH POTENTIAL OF ERYASPASE AND ERYMETHIONASE IN TREATMENT OF SOLID TUMORS.  Full Article

Erytech FY Net Loss Widens To 33.5 Million Euros
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Erytech ::REPORTED ON MONDAY FY NET LOSS 33.5 MILLION EUROS, COMPARED TO 21.9 MILLION EUROS IN 2016.CASH POSITION OF 185.5 MILLION EUROS AT YEAR-END.FY TOTAL OPERATING LOSS 30.9 MILLION EUROS VS LOSS 22.4 MILLION EUROS YR AGO .  Full Article

Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - ERYTECH PHARMA SA ::‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE​.‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018​.  Full Article

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
Friday, 8 Dec 2017 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.  Full Article

BRIEF-Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros

* REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO